Engineering Bispecifics at PEGS Europe 2019 presents truly novel engineering approaches such as new high throughput screening for target discovery, synergistic pair combinations and key bispecific parameters. In addition, engineering for improved targeting with proven functionality, enhanced potency and minimal tox will be showcased. It focuses on challenging areas such as crossing the blood brain barrier, ophthalmology, overcoming bacterial and viral resistance, and Treg selection. We present data-rich case studies that report on difficulties encountered and overcome.
INSIGHTS INTO BISPECIFIC MECHANISMS THAT WORK
KEYNOTE PRESENTATION: Biophysical Characterization to Determine the Impact of Different Mechanisms of Bispecific Molecules
Andreas Plueckthun, PhD, Professor & Director, Biochemistry, University of Zurich
Lisbon Wasn’t Built in a Day – Alternative Scaffolds Gain Momentum
H. Kaspar Binz, PhD, Binz Biotech Consulting
NEW PLATFORMS FOR DISCOVERY, PRODUCTION AND IDENTIFICATION OF SYNERGISTIC TARGET PAIRS
A Simple IgG-like Discovery Platform for a Complex IgG-Like (1+1) Format
Régis Cebe, MSc, Scientific Technical Leader, Novartis Biologic Centre, Novartis Institute of Biomedical Research
A New Platform for the Identification of Synergistic Bispecific Combinations
Elke Glasmacher, PhD, Head, Immunobiology, Large Molecule Research, pRED, Roche Innovation Center
FOCUS ON T-CELL ACTIVATION, PK, AFFINITY AND MAXIMIZING THE THERAPEUTIC INDEX
Dual Agonist Bispecific Antibody Targeting OX40 and CD137 Mediates Anti-Tumour Immunity and Synergises with PD-1/PD-L1 Blockade to Improve Survival in a Syngeneic Mouse Model
Mihriban Tuna, PhD, SVP, Drug Discovery, F-star
Optimization of Preclinical Safety and Efficacy of Anti-HER2/CD3
Teemu Junttila, PhD, Senior Scientist, Translational Oncology, Genentech, Inc.
Concept to Clinic: Development of Fc-Containing XmAb® Bispecific Antibodies for Immunotherapy
Umesh Muchtal, PhD, Director, Molecular Biology & Protein Sciences Xencor, Inc.
Ulrich Brinkmann, PhD, Expert Scientist, Large Molecule Research, Roche Pharma Research & Early Development, Roche
TCER® Platform: Targeting of Tumor-Specific HLA Ligands using T Cell Receptor Bispecifics
Sebastian Bunk, PhD, Immunology, Immatics Biotechnologies GmbH
ENGINEERING FOR AUTOIMMUNE DISEASE AND TO OVERCOME VIRAL RESISTANCE
Preclinical Development of Xmab27564, a Long-Acting IL2-Fc Fusion Protein, as a Novel Treg-Selective Therapy for Autoimmune Diseases
Suzanne Schubbert, PhD, Lead Scientist, Cell Biology, Xencor, Inc.
Multi-Specific Agent to Overcome Potential Resistance to Influenza
Mark Chiu, PhD, Associate Director, Structural Biology, Janssen
HIGH THROUGHPUT SCREENING APPROACHES FOR BISPECIFICS
Bispecific Target Discovery by High Throughput Functional Screening
Pallavi Bhatta. PhD, Principal Scientist, Bispecific Target Discovery, UCB
NestLink Technology to Determine Key Pharmacokinetic Parameters of Hundreds of Bispecifics Simultaneously
Pascal Egloff, PhD, Platform Leader, Medical Microbiology, University of Zurich
CROSSING THE BLOOD BRAIN BARRIER
Brain Penetrant Bispecific Agonist Antibodies to Neurotrophin Receptors Trkb and Trkc
Frank S. Walsh, PhD, CEO, Ossianix, Inc.
* The program is subject to change without notice, due to unforeseen reason.